October is Breast Cancer Awareness Month. There is good news for women fighting bone-loss after treatment.
The bone density drug Zoledronic Acid is prescribed to fight Osteoporosis especially in post-menopausal women.
It has been given to breast cancer patients for the same reasons.
Now, in a new study published in the journal cancer, researchers say
the drug is doing its job.
Patients took the drug both at the start of their breast cancer therapy and others waited 36 months after starting treatment.
Taking the drug at the start protected against bone loss in the lower
spine and hip.